Nucleoside Deaminases
-
Subject Areas on Research
- A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution.
- A role for adenosine deaminase in human monocyte maturation.
- A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.
- ADA deficiency treatment.
- Abnormalities in S-adenosylhomocysteine hydrolysis, ATP catabolism, and lymphoid differentiation in adenosine deaminase deficiency.
- Adenosine deaminase (ADA) deficiency due to deletion of the ADA gene promoter and first exon by homologous recombination between two Alu elements.
- Adenosine deaminase and purine nucleoside phosphorylase deficiencies: evaluation of therapeutic interventions in eight patients.
- Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase.
- Altered regulation of S-adenosylmethionine dependent methylation in adenosine deaminase deficiency.
- Biochemical consequences of adenosine deaminase inhibition in vivo. Differential effects in acute and chronic T cell leukemia.
- Comparison of red cell transfusion and polyethylene glycol-modified adenosine deaminase therapy in an adenosine deaminase-deficient child: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool.
- Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
- Elucidation of aberrant purine metabolism: application to hypoxanthine-guanine phosphoribosylstransferase- and adenosine kinase-deficient mutants, and IMP dehydrogenase- and adenosine deaminase-inhibited human lymphoblasts.
- Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.
- Further investigation of simian immunodeficiency virus Vif function in human cells.
- HIV-1 Vif: counteracting innate antiretroviral defenses.
- Identification of a deletion in the adenosine deaminase gene in a child with severe combined immunodeficiency.
- Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector.
- In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients.
- Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
- Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.
- Paradoxical expression of adenosine deaminase in T cells cultured from a patient with adenosine deaminase deficiency and combine immunodeficiency.
- Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.
- S-Adenosylhomocysteine metabolism in adenosine deaminase deficient cells.
- S-adenosylhomocysteine hydrolase is an adenosine-binding protein: a target for adenosine toxicity.
- Selective inhibition of Alu retrotransposition by APOBEC3G.
- Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
- The human genes for S-adenosylhomocysteine hydrolase and adenosine deaminase are syntenic on chromosome 20.
- The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains.
- Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase.
-
Keywords of People
- Buckley, Rebecca Hatcher, Professor Emeritus of Pediatrics, Pediatrics, Allergy and Immunology